Genomma Lab USA sold two hydroquinone skin-lightening creams as unapproved and misbranded new drugs, FDA says.
What happened
FDA reviewed the labels of Cicatricure® MEDICAL LIGHTENING SKIN LIGHTENING CREAM and teatrical® PRO-ACLARANT SKIN LIGHTENING NIGHT CREAM and found claims that they lighten dark spots, with hydroquinone 2% listed as the active ingredient. FDA says this makes them skin-bleaching drugs that need an approved new drug application, but no approved application is in effect, so they are unapproved new drugs and misbranded. The letter does not describe an inspection.
What FDA found
The two creams are unapproved new drugs because no FDA-approved drug application is in effect for them.
FD&C Act section 505(a), 21 U.S.C. 355(a)The creams are misbranded because they are nonprescription drugs that do not meet the legal requirements for marketing without an approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee); section 505G, 21 U.S.C. 355hThe products were introduced into interstate commerce even though they are unapproved and misbranded.
FD&C Act sections 301(a) and 301(d), 21 U.S.C. 331(a), 331(d)FDA has proposed that OTC skin-bleaching products with hydroquinone are not generally recognized as safe and effective, so the creams are deemed new drugs needing approval.
FD&C Act section 201(p)(1), 21 U.S.C. 321(p)(1); section 505G(a)(4), 21 U.S.C. 355h(a)(4)
What FDA wants
FDA tells the company to respond in writing within 15 working days, explain what it has done to correct the violations and prevent recurrence, and if it cannot finish, give reasons and a completion schedule. If the company believes the products are not in violation, it should include its reasoning and supporting information.
Who should pay attention
- retailers and distributors that sell skin-lightening creams
- brands marketing OTC skin-bleaching products with hydroquinone
- companies relying on FDA drug listings or export certificates
This is a summary. Read the original letter on fda.gov.